MYELOID NEOPLASIA A gene expression signature of CD34 cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
نویسندگان
چکیده
1Oregon Health & Science University Knight Cancer Institute, Portland; 2Academic Haematology, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 3Gene Microarray Shared Resource, Oregon Health & Science University, Portland; 4Clinical Programs, Pathwork Diagnostics, Redwood City, CA; 5Integrative Computational Sciences, Lilly Singapore Centre for Drug Discovery, Singapore; 6Howard Hughes Medical Institute, Chevy Chase, MD; 7Department of Haematology, Institute of Medical & Veterinary Science, Adelaide, Australia; and 8Department of Hematology, University of Leipzig, Leipzig, Germany
منابع مشابه
Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملA gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (< 36% Ph(+) metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34(+) cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. Th...
متن کاملImpact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response
Background: Imatinib mesylate (IM), a strong and selective tyrosine kinase inhibitor, has been approved as the front line of treatment in chronic myeloid leukemia (CML) patients. In spite of satisfactory results of imatinib in the treatment of patients with CML, patients with treatment failure or suboptimal response developed resistance that might be because of pharmacogenetic variants. This st...
متن کاملDetection of abl/bcr Fusion Gene in Patients Affected by Chronic Myeloid Leukaemia by Dual-Colour Interphase Fluorescence in situ Hybridisation
Conventional cytogenetic is the standard technique for detection of Philadelphia (Ph) chromosome in chronic myeloid leukemia (CML). Evaluation of abelson murine leukemia/breakpoint cluster region (abl/bcr) fusion using dual-colour fluorescence in situ hybridization (D-FISH) is an alternative approach allowing rapid and reliable detection of the disease. We employed the technique of interphase D...
متن کاملStudy of STAT3 Expression in Different Phases of Patients with Chronic Myeloid Leukemia
Background and Aim: Chronic myeloid leukemia(CML) is a clonal myeloproliferative disease, characterized by BCR/ABL translocation. Using tyrosine kinase inhibitors such as Imatinib, treatment for this disease has progressed remarkably. However, resistance to tyrosine kinase inhibitor is a major obstacle. Signal transducer and activator of transcription 3(STAT3) is an important transcription fact...
متن کامل